Pathogenesis of ligaments ossification in spondyloarthritis: insights and doubts

References

• Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Benjamin M, Marzo-Ortega H, Emery P. Advances in the understanding of entheseal inflammation. Curr Rheumatol Rep. 2002;4:500–6.
   PubMedGoogle Scholar
• Benjamin M, Evans EJ, Copp L. The histology of tendon attachments to bone in man. J Anat. 1986;149:89–100.
   PubMed Web of Science ®Google Scholar
• Benjamin M, McGonagle D. Entheses: tendon and ligament attachment sites. Scand J Med Sci Sports. 2009;19:520–7.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998;352:1137–40.
   PubMed Web of Science ®Google Scholar
• Laloux L, Voisin MC, Allain J, Martin N, Kerboull L, Chevalier X, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001;60:316–21.
   PubMed Web of Science ®Google Scholar
• Las Heras F, Pritzker KP, So A, Tsui HW, Chiu B, Inman RD, et al. Aberrant chondrocyte hypertrophy and activation of β-catenin signaling precede joint ankylosis in ank/ank mice. J Rheumatol. 2012;39:583–93.
   PubMed Web of Science ®Google Scholar
• Ball J. The enthesopathy of ankylosing spondylitis. Br J Rheumatol. 1983;22: 25–8.
   PubMedGoogle Scholar
• Tran TM, Dorris ML, Satumtira N, Richardson JA, Hammer RE, Shang J, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum. 2006;54:1317–27.
   PubMed Web of Science ®Google Scholar
• van Duivenvoorde LM, Dorris ML, Satumtira N, van Tok MN, Redlich K, Tak PP, et al. Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2-microglobulin-transgenic rat model of spondylarthritis. Arthritis Rheum. 2012;64:3210–19.
   PubMed Web of Science ®Google Scholar
• Kontoyianni D, Pasparakis M, Pizarro TT, Cominellim F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10:387–98.
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Pasparaki M, Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol. 1997;27:2588–92.
   PubMed Web of Science ®Google Scholar
• Edwards CK, Bendele AM, Reznikov LI, Fantuzzi G, Chlipala ES, Li L, et al. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. Arthritis Rheum. 2006;54:2872–85.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Wakefield RJ, Tan AL, D'Agostino MA, Toumi H, Hayashi K, et al. Distinct topography of erosion and new bone formation in achilles tendon enthesitis: implications for understanding the link between inflammation and bone formation in spondylarthritis. Arthritis Rheum. 2008;58:2694–9.
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505.
   PubMed Web of Science ®Google Scholar
• Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24:518–23.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014;73:1819–25.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11:R127.
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645–54.
   PubMed Web of Science ®Google Scholar
• Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol. 2014;26:361–70.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt + CD3 + CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069–76.
   PubMed Web of Science ®Google Scholar
• Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci U S A. 2011;108:9560–5.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2009;60:955–65.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Accardo-Palumbo A, Alessandro R, Rizzo A, Principe S, Peralta S, et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum. 2012;64:1869–78.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:1739–47.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–13.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73:349–56.
   PubMed Web of Science ®Google Scholar
• Xueyi L, Lina C, Zhenbiao W, Qing H, Qiang L, Zhu P. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol. 2013;33:151–61.
   PubMed Web of Science ®Google Scholar
• Abe Y, Ohtsuji M, Ohtsuji N, Lin Q, Tsurui H, Nakae S, et al. Ankylosing enthesitis associated with up-regulated IFN-gamma and IL-17 production in (BXSB × NZB) F(1) male mice: a new mouse model. Mod Rheumatol. 2009;19:316–22.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Joosten LAB, van de Loo FAJ, Schwarzenberger P, Kolls J, van den Berg WB. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res. 2002;51:102–4.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004;50:650–9.
   PubMed Web of Science ®Google Scholar
• Li J. JAK-STAT and bone metabolism. JAKSTAT. 2013;2:e23930.
   PubMedGoogle Scholar
• Nicolaidou V, Wong MM, Redpath AN, Ersek A, Baban DF, Williams LM, et al. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One. 2012;7:e39871.
   PubMed Web of Science ®Google Scholar
• Asari T, Furukawa K, Tanaka S, Kudo H, Mizukami H, Ono A, et al. Mesenchymal stem cell isolation and characterization from human spinal ligaments. Biochem Biophys Res Commun. 2012;417:1193–9.
   PubMed Web of Science ®Google Scholar
• Beckmann JH, Yan S, Luhrs H, Heid B, Skubich S, Forster R, et al. Prolongation of allograft survival in ccr7-deficient mice. Transplantation. 2004;77:1809–14.
   PubMed Web of Science ®Google Scholar
• Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, et al. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol. 2005;6:889–94.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Iwama N, Date F, Shibata N, Miki H, Yamauchi K, et al. Role of chemokines in tumor growth. Cancer Lett. 2007;256:137–65.
   PubMed Web of Science ®Google Scholar
• Sato S, Takahashi T, Ono M. Macrophages participate in lymphangiogenesis in idiopathic diffuse alveolar damage through CCL19-CCR7 signal. Hum Pathol. 2009;40:1553–63.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Sun L, Yin L, Ming J, Zhang S, Luo W, et al. CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer. Tumour Biol. 2013;34:2703–8.
   PubMed Web of Science ®Google Scholar
• Qin Y, He LD, Sheng ZJ, Yong MM, Sheng YS, Wei Dong X, et al. Increased CCL19 and CCL21 levels promote fibroblast ossification in ankylosing spondylitis hip ligament tissue. BMC Musculoskelet Disord. 2014;15:316.
   PubMed Web of Science ®Google Scholar
• Yu F, Cui Y, Zhou X, Zhang X, Han J. Osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclast-like cells. Biosci Trends. 2011;5:46–51.
   PubMed Web of Science ®Google Scholar
• Yang M, Yuan H, Miao M, Xu W. The osteogenic potential of ligament fibroblasts is greater in ankylosing spondylitis patients than in patients with osteoarthritis. Z Rheumatol. 2015;74:340–5.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Furushima K, Sugimori K, Inoue I, Kimura T. Association between polymorphism of the transforming growth factor-beta1 gene with the radiologic characteristic and ossification of the posterior longitudinal ligament. Spine (Phila Pa 1976). 2003;28:1424–6.
   PubMed Web of Science ®Google Scholar
• Inaba K, Matsunaga S, Ishidou Y, Imamura T, Yoshida H. Effect of transforming growth factor-beta on fibroblasts in ossification of the posterior longitudinal ligament. In Vivo. 1996;10:445–9.
   PubMed Web of Science ®Google Scholar
• Ishida Y. Studies on induction mechanism of ossification of the posterior longitudinal ligament of the spine–especially on the cultured cells from the human spinal ligament. Nihon Seikeigeka Gakkai Zasshi. 1988;62:1019–27.
   PubMedGoogle Scholar
• François RJ, Neure L, Siepe J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006;65:713–20.
   PubMed Web of Science ®Google Scholar
• Ogasawara T, Kawaguchi H, Jinno S, Hoshi K, Itaka K, Takato T, et al. Bone morphogenetic protein 2-induced osteoblast differentiation requires Smad-mediated down-regulation of Cdk6. Mol Cell Biol. 2004;24:6560–8.
   PubMed Web of Science ®Google Scholar
• Osyczka AM, Leboy PS. Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling. Endocrinology. 2005;146:3428–37.
   PubMed Web of Science ®Google Scholar
• Hoshi K, Amizuka N, Sakou T, Kurokawa T, Ozawa H. Fibroblasts of spinal ligaments pathologically differentiate into chondrocytes induced by recombinant human bone morphogenetic protein-2: morphological examinations for ossification of spinal ligaments. Bone. 1997;21:155–62.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ishidou Y, Yonemori K, Nagamine T, Origuchi N, Maeda S, et al. Expression and localization of bone morphogenetic proteins (BMPs) and BMP receptors in ossification of the ligamentum flavum. Bone. 1997;21:23–30.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Nagai E, Murata H, Tsubone T, Shirakura Y, Sugiyama T, et al. Involvement of bone morphogenic protein-2 (BMP-2) in the pathological ossification process of the spinal ligament. Rheumatology (Oxford). 2001;40:1163–8.
   PubMed Web of Science ®Google Scholar
• Fukui N, Ikeda Y, Ohnuki T, Hikita A, Tanaka S, Yamane S, et al. Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional up-regulation. J Biol Chem. 2006;281:27229–41.
   PubMed Web of Science ®Google Scholar
• Yan L, Chang Z, Liu Y, Li YB, He BR, Hao DJ. A single nucleotide polymorphism in the human bone morphogenetic protein-2 gene (109T > G) affects the Smad signaling pathway and the predisposition to ossification of the posterior longitudinal ligament of the spine. Chin Med J (Engl). 2013;126:1112–18.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang ZH, Liu DM, Wang L, Meng XL, Tian BP. Association between two polymorphisms of the bone morpho-genetic protein-2 gene with genetic susceptibility to ossification of the posterior longitudinal ligament of the cervical spine and its severity. Chin Med J (Engl). 2008;121:1806–10.
   PubMed Web of Science ®Google Scholar
• Nusse R, Varmus H. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31:99–109.
   PubMed Web of Science ®Google Scholar
• Chen Y, Whetstone HC, Youn A, Nadesan P, Chow EC, Lin AC, et al. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem. 2007;282:526–33.
   PubMed Web of Science ®Google Scholar
• Bougault C, Briolay A, Boutet MA, Pilet P, Delplace S, Le Goff B, et al. Wnt5a is expressed in spondyloarthritis and exerts opposite effects on enthesis and bone in murine organ and cell cultures. Transl Res. 2015;166:627–38.
   PubMed Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156–63.
   PubMed Web of Science ®Google Scholar
• Lories RJU, Luyten FP, deVlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther. 2009;11:221.
   PubMed Web of Science ®Google Scholar
• Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int. 2012;32:2523–7.
   PubMed Web of Science ®Google Scholar
• Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2012;13:191.
   PubMed Web of Science ®Google Scholar
• Nocturne G, Pavy S, Boudaoud S, Seror R, Goupille P, Chanson P, et al. Increase in Dickkopf-1 serum level in recent spondyloarthritis. Data from the DESIR Cohort. PLoS One. 2015;10:e0134974.
   Google Scholar
• Sakellariou GT, Iliopoulos A, Konsta M, Kenanidis E, Potoupnis M, Tsiridis E, et al. Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters. Joint Bone Spine. 2016. [Epub ahead of print].
   PubMedGoogle Scholar
• Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010;62:150–8.
   PubMed Web of Science ®Google Scholar
• Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60:3257–62.
   PubMed Web of Science ®Google Scholar
• Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Kucharska E, et al. High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord. 2013;14:99.
   PubMed Web of Science ®Google Scholar
• Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69:2152–9.
   PubMed Web of Science ®Google Scholar
• Aschermann S, Englbrecht M, Bergua A, Spriewald BM, Said-Nahal R, Breban M, et al. Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway. Joint Bone Spine. 2016;83:43–6.
   PubMed Web of Science ®Google Scholar
• Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in drosophila. Cell. 2003;113:25–36.
   PubMed Web of Science ®Google Scholar
• Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5:396–400.
   PubMed Web of Science ®Google Scholar
• Roberto VP, Tiago DM, Silva IA, Cancela ML. MiR-29a is an enhancer of mineral deposition in bone-derived systems. Arch Biochem Biophys. 2014;564:173–83.
   PubMed Web of Science ®Google Scholar
• Huang J, Song G, Yin Z, Luo X, Ye Z. Elevated miR-29a expression is not correlated with disease activity index in PBMCs of patients with ankylosing spondylitis. Mod Rheumatol. 2014;24:331–4.
   PubMed Web of Science ®Google Scholar
• Lv Q, Li Q, Zhang P, Jiang Y, Wang X, Wei Q, et al. Disorders of MicroRNAs in peripheral blood mononuclear cells: as novel biomarkers of ankylosing spondylitis and provocative therapeutic targets. Biomed Res Int. 2015;2015:504208.
   PubMed Web of Science ®Google Scholar
• Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol. 2007;26:710–14.
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Sidiropoulos PI, Karvounaris SA, Vrentzos GE, Spanakis EK, Ganotakis ES, et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFα treatment: correlation with disease activity. Clin Exp Rheumatol. 2009;27:292–8.
   PubMed Web of Science ®Google Scholar
• Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212:E1–19.
   PubMed Web of Science ®Google Scholar
• Turner RT, Kalra SP, Wong CP, Philbrick KA, Lindenmaier LB, Boghossian S, et al. Peripheral leptin regulates bone formation. J Bone Miner Res. 2013;28:22–34.
   PubMed Web of Science ®Google Scholar
• Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002;175:405–15.
   PubMed Web of Science ®Google Scholar
• Hulejová H, Levitová A, Kuklová M, Stochl J, Haluzík M, Pavelka K, et al. No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clin Rheumatol. 2012;31:67–71.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huédé G, Saas P, et al. Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metab Clin Exp. 2007;56:1383–9.
   PubMed Web of Science ®Google Scholar
• Sari I, Demir T, Kozaci LD, Akar S, Kavak T, Birlik M, et al. Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol. 2007;26:1427–32.
   PubMed Web of Science ®Google Scholar
• Park MC, Lee SW, Choi ST, Park YB, Lee SK. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol. 2007;36:101–6.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hartl A, Hermann KG, Rudwaleit M, Sieper J. Higher serum level of leptin might be responsible for less structural damage in the spine in female patients with ankylosing spondylitis. Ann Rheum Dis. 2016;75:84–5.
   PubMed Web of Science ®Google Scholar
• Kanazawa I. Adiponectin in metabolic bone disease. Curr Med Chem. 2012;19:5481–92.
   PubMed Web of Science ®Google Scholar
• Derdemezis CS, Filippatos TD, Voulgari PV, Tselepism AD, Drosos AA, Kiortsis DN. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment. Clin Exp Rheumatol. 2010;28:880–3.
   PubMed Web of Science ®Google Scholar
• Syrbe U, Callhoff J, Conrad K, Poddubnyy D, Haibel H, Junker S, et al. Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. Arthritis Rheumatol. 2015;67:678–85.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, et al. Ghrelin directly regulates bone formation. J Bone Miner Res. 2005;20:790–8.
   PubMed Web of Science ®Google Scholar
• Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone. 2005;37:359–69.
   PubMed Web of Science ®Google Scholar
• Yayama T, Uchida K, Kobayashi S, Kokubo Y, Sato R, Nakajima H, et al. Thoracic ossification of the human ligamentum flavum: histopathological and immunohistochemical findings around the ossified lesion. J Neurosurg Spine. 2007;7:184–93.
   PubMed Web of Science ®Google Scholar
• Appel H, Kuhne M, Spiekermann S, Köhler D, Zacher J, Stein H, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum. 2006;54:1805–13.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Hetland ML, Sørensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol. 2010;29:1301–9.
   PubMed Web of Science ®Google Scholar
• Lin TT, Lu J, Qi CY, Yuan L, Li XL, Xia LP, et al. Elevated serum level of IL-27 and VEGF in patients with ankylosing spondylitis and associate with disease activity. Clin Exp Med. 2015;15:227–31.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis. 2011;70:1375–81.
   PubMed Web of Science ®Google Scholar
• Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther. 2008;10:R125.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 2008;67:511–17.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, Xu S, Hsu B. Serum vascular endothelial growth factor levels lack predictive value in patients with active ankylosing spondylitis treated with golimumab. J Rheumatol. 2016;43:901–6.
   PubMed Web of Science ®Google Scholar
• Jacques P, Lambrecht S, Verheugen E, Pauwels E, Kollias G, Armaka M, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis. 2014;73:437–45.
   PubMed Web of Science ®Google Scholar